Compared with the diabetes group, the levels of inflammatory markers, such as cytokines IL-1β and tumor necrosis factor alpha (TNF-α), were significantly decreased both in the serum and pancreas with DFE administration (Figure 5A), suggesting that DFE could alleviate severe inflammation in the diabetic pancreas. The gene discussed is IL1B; the disease is diabetes mellitus.